tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Low Back Pain
Conditions
Low Back Pain
Trial Timeline
Dec 1, 2007 → May 1, 2008
NCT ID
NCT00594516About tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR) is a phase 3 stage product being developed by Johnson & Johnson for Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00594516. Target conditions include Low Back Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00594516 | Phase 3 | Completed |
Competing Products
20 competing products in Low Back Pain